Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
Generated Narrative: Group 236534
version: 67; Last updated: 2025-03-20 18:40:09+0000
Profile: ComparatorGroup
Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Group/236534
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236534, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85390-C-85789
title: Standard care Group in Adults with type 2 diabetes with moderate CV risk
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
description:
Standard care
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparatorGroup |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
type: Person
membership: Enumerated
combinationMethod: All of
characteristic
code: Member of
value: Adults with type 2 diabetes and established CVD (but no CKD)
exclude: false
description:
inclusion in Adults with type 2 diabetes with moderate CV risk
characteristic
code: Exposed to
value: Standard care
exclude: false
description:
received Standard care